Skip to content
Inciteful Med
Resources About us Ask a Question

What Does STAT6 Positive Mean on a Pathology Report?

Published: | Updated:

A "STAT6 positive" pathology report is a highly reliable confirmation of a solitary fibrous tumor (SFT). It means your tumor contains the NAB2-STAT6 gene fusion, a unique molecular fingerprint. While it confirms the diagnosis, it does not predict how aggressive the tumor will be.

Key Takeaways

  • • A STAT6 positive result strongly confirms a diagnosis of solitary fibrous tumor (SFT).
  • • This result is caused by the NAB2-STAT6 gene fusion, a random genetic error found only in the tumor cells.
  • • Pathologists use immunohistochemistry (IHC) testing to look for the abnormal STAT6 protein.
  • • STAT6 positivity rules out other similar-looking tumors, preventing misdiagnosis.
  • • The STAT6 test identifies the tumor type but does not predict its future behavior or aggressiveness.

If you are reading your pathology report and see the phrase “STAT6 positive,” this is a highly reliable confirmation that your tumor is a Solitary Fibrous Tumor (SFT) [1][2]. Pathologists look for this specific marker because it acts as the molecular fingerprint for this exact disease. Getting an accurate diagnosis of an ultra-rare sarcoma like an SFT can be a stressful, confusing journey, but this finding is the key that finally identifies exactly what you are facing.

The Science Behind the Result

To understand why this happens, it helps to look at the genetics of the tumor. SFTs are driven by a specific genetic event called the NAB2-STAT6 gene fusion [3][4]. In the DNA of the tumor cells, two separate genes—NAB2 and STAT6—accidentally merge or fuse together on chromosome 12 [5][6].

This is an acquired somatic mutation, meaning it is a random genetic error that occurred only in the tumor cells, not an inherited trait that you can pass on to your children.

This fusion acts as a “switched-on” engine that drives the tumor’s growth [7]. It also causes the cells to produce an abnormal fusion protein that accumulates inside the nucleus (the control center) of the cell [8][9].

How the Test Works

When a piece of your tumor is biopsied or removed, it is sent to a lab where pathologists run a specialized test called immunohistochemistry (IHC) [2]. You do not undergo this test yourself; instead, the pathologist applies customized chemical stains to extremely thin slices of the tumor tissue on a glass slide.

These stains are designed to stick directly to the abnormal STAT6 protein. If the nucleus of the tumor cells lights up strongly with the stain under the microscope, the tumor is designated as “STAT6 positive” [1][10].

Why This Finding Is Crucial

Under a standard microscope, an SFT is classified as a “spindle cell neoplasm,” meaning the cells look long, narrow, and spindle-shaped [11][12]. The challenge is that dozens of other soft tissue tumors and sarcomas look almost exactly the same [11]. This is why many SFTs are initially misdiagnosed before specialized pathology testing is performed.

Because STAT6 positivity is highly sensitive and specific to SFTs [1][13], this marker allows doctors to confidently rule out similar-looking conditions—such as meningioma, myofibroblastoma, or other types of sarcomas—and establish an accurate SFT diagnosis [11][12][13]. It is especially useful in modern pathology because it works reliably even if other common tumor markers (like CD34) test negative [13][11]. Due to the rarity of SFTs, it is always recommended to have your pathology report reviewed by an expert at a specialized sarcoma center.

What STAT6 Does Not Tell You

While a STAT6 positive result tells you exactly what the tumor is, it does not predict how the tumor will behave over time. Specifically, the level of STAT6 positivity cannot determine whether the tumor is likely to act aggressively [14][15].

Medical experts generally do not classify SFTs using a simple “benign” (non-cancerous) or “malignant” (cancerous) label, as all SFTs are considered to have at least some potential to spread (metastasize) over time. Instead, your pathologist will evaluate completely different factors to calculate a risk score (using systems like the Demicco criteria). To determine if your tumor is low, intermediate, or high risk, they will look at your age, the size of the tumor, the mitotic count (how rapidly the tumor cells are dividing), and whether there are areas of dead cell tissue, known as necrosis [14][16].

Frequently Asked Questions

What does a STAT6 positive result mean on my pathology report?
A STAT6 positive result is a highly reliable marker that confirms a solitary fibrous tumor (SFT) diagnosis. It means the pathologist found a specific abnormal protein in your tumor cells.
Is the STAT6 genetic mutation inherited?
No, the NAB2-STAT6 gene fusion is an acquired somatic mutation. This means it is a random genetic error that only occurs in the tumor cells and cannot be passed down to your children.
Does a STAT6 positive result mean my tumor is cancer?
SFTs are not strictly classified as benign or malignant, as all have some potential to spread. While STAT6 confirms what the tumor is, your doctor will use other factors like mitotic count and tumor size to calculate its risk level.
Why is STAT6 testing necessary if I already had a biopsy?
Under a microscope, SFT cells look like many other soft tissue tumors. STAT6 testing uses a specialized stain that allows pathologists to confidently rule out similar conditions and confirm an exact SFT diagnosis.

Questions for Your Doctor

  • • Does my pathology report include a formal risk score, such as the Demicco criteria, to help predict how this tumor might behave?
  • • What is the exact mitotic count of my tumor, and were there any signs of necrosis?
  • • Since SFT is an ultra-rare sarcoma, can my pathology slides be sent to a specialized sarcoma center for a second opinion?
  • • Besides STAT6, were there any other positive or negative markers on my pathology report that I should be aware of?

Questions for You

  • • Has my pathology report been reviewed by a sarcoma specialist, or was it evaluated by a general community pathologist?
  • • Do I have a complete physical or digital copy of my full pathology report so I can understand the size, mitotic count, and other features beyond the STAT6 result?
  • • What are my primary goals for my upcoming oncology appointment—am I looking for treatment options, or simply a clearer explanation of my specific risk level?

Want personalized information?

Type your question below to get evidence-based answers tailored to your situation.

References

  1. 1

    Cutaneous solitary fibrous tumor: Report of three cases with review of histopathological mimics.

    Vincek V, Kallis P, Vause A, et al.

    Journal of cutaneous pathology 2022; (49(2)):167-171 doi:10.1111/cup.14138.

    PMID: 34569103
  2. 2

    Molecular characterization of a series of solitary fibrous tumors, including immunohistochemical expression of STAT6 and NATB2-STAT6 fusion transcripts, using Reverse Transcriptase(RT)-Polymerase chain reaction(PCR) technique: An Indian experience.

    Rekhi B, Shetty O, Tripathi P, et al.

    Pathology, research and practice 2017; (213(11)):1404-1411 doi:10.1016/j.prp.2017.08.011.

    PMID: 28869107
  3. 3

    Solitary Fibrous Tumor in the Retroperitoneal Space Arising from the Diaphragm.

    Seito T, Kaneko T, Kawai T, et al.

    In vivo (Athens, Greece) 2023; (37(6)):2849-2853 doi:10.21873/invivo.13401.

    PMID: 37905637
  4. 4

    A review of solitary fibrous tumours of the orbit and ocular adnexa.

    René C, Scollo P, O'Donovan D

    Eye (London, England) 2023; (37(5)):858-865 doi:10.1038/s41433-022-02160-w.

    PMID: 35831617
  5. 5

    Diagnostics and Treatment of Extrameningeal Solitary Fibrous Tumors.

    Janik AM, Terlecka A, Spałek MJ, et al.

    Cancers 2023; (15(24)) doi:10.3390/cancers15245854.

    PMID: 38136399
  6. 6

    FNA cytology of solitary fibrous tumors and the diagnostic value of STAT6 immunocytochemistry.

    Tani E, Wejde J, Åström K, et al.

    Cancer cytopathology 2018; (126(1)):36-43 doi:10.1002/cncy.21923.

    PMID: 28914981
  7. 7

    A Novel NFIX-STAT6 Gene Fusion in Solitary Fibrous Tumor: A Case Report.

    Moura DS, Díaz-Martín J, Bagué S, et al.

    International journal of molecular sciences 2021; (22(14)) doi:10.3390/ijms22147514.

    PMID: 34299133
  8. 8

    Adenofibromatous Solitary Fibrous Tumor: An Unusual Morphologic Variant Occurring in the Sinonasal Tract.

    Kwok ALM, Chan JKC, Tang AHN, et al.

    Head and neck pathology 2023; (17(1)):165-171 doi:10.1007/s12105-022-01490-1.

    PMID: 36166160
  9. 9

    Intracranial solitary fibrous tumor/ hemangiopericytoma with osteoclast-like multinucleated giant cells: comparison with giant cell-rich solitary fibrous tumor.

    Vizcaíno MA, Bishop J, Sharma R, et al.

    Clinical neuropathology 2016; (35(4)):171-7 doi:10.5414/NP300933.

    PMID: 27049065
  10. 10

    STAT6 Expression in Solitary Fibrous Tumor and Histologic Mimics: a Single Institution Experience.

    Saeed O, Zhang S, Cheng L, et al.

    Applied immunohistochemistry & molecular morphology : AIMM 2020; (28(4)):311-315 doi:10.1097/PAI.0000000000000745.

    PMID: 30664532
  11. 11

    STAT6 expression in spindle cell lesions of the breast: An immunohistochemical study of 48 cases.

    Magro G, Spadola S, Motta F, et al.

    Pathology, research and practice 2018; (214(10)):1544-1549 doi:10.1016/j.prp.2018.07.011.

    PMID: 30072169
  12. 12

    Solitary fibrous tumor of male breast: A case report and literature review.

    Kawaguchi S, Kinowaki K, Tamura N, et al.

    Medicine 2022; (101(50)):e32199 doi:10.1097/MD.0000000000032199.

    PMID: 36550858
  13. 13

    NAB2-STAT6 fusion types account for clinicopathological variations in solitary fibrous tumors.

    Tai HC, Chuang IC, Chen TC, et al.

    Modern pathology : an official journal of the United States and Canadian Academy of Pathology, Inc 2015; (28(10)):1324-35 doi:10.1038/modpathol.2015.90.

    PMID: 26226844
  14. 14

    The clinicopathological significance of NAB2-STAT6 gene fusions in 52 cases of intrathoracic solitary fibrous tumors.

    Huang SC, Li CF, Kao YC, et al.

    Cancer medicine 2016; (5(2)):159-68 doi:10.1002/cam4.572.

    PMID: 26686340
  15. 15

    Solitary fibrous tumour of the genitourinary tract: a clinicopathological study of 11 cases and their association with the NAB2-STAT6 fusion gene.

    Kouba E, Simper NB, Chen S, et al.

    Journal of clinical pathology 2017; (70(6)):508-514 doi:10.1136/jclinpath-2016-204088.

    PMID: 27802414
  16. 16

    NAB2-STAT6 gene fusion and STAT6 immunoexpression in extrathoracic solitary fibrous tumors: the association between fusion variants and locations.

    Chuang IC, Liao KC, Huang HY, et al.

    Pathology international 2016; (66(5)):288-96 doi:10.1111/pin.12408.

    PMID: 27039712

This page explains STAT6 pathology terminology for educational purposes. Always consult your pathologist and oncologist for a personalized interpretation of your pathology report.

Stay up to date

Get notified when new research about Solitary Fibrous Tumor (SFT) is published.

No spam. Unsubscribe anytime.